NVision Imaging raises $30M Series A to deploy quantum-powered polarizers and usher in a new era of adaptive cancer treatment
Our portfolio company NVision Imaging, a developer of MRI polarizers and hyperpolarized imaging agents, announced that they have closed a $30M Series A round, with an additional $19.5M in funding from the German government. The company will use the funds to advance the development and deployment of the NVision Polarizer and usher in a new era of metabolic MRI capabilities and ultimately, adaptive cancer treatment. The round was led by Playground Global, with participation by existing investors and new participation from Pathena Investments, Entree Capital, Lauder Family, ES Kapital, and Sparkassenkapital Ulm, bringing their total funding to $35M, not including the government funds.
Unlike traditional polarizers that are slow, cumbersome to use, and complicated to operate in the MRI setting, NVision’s Polarizer is fast, robust, and easy-to-use. Based on a novel parahydrogen-induced polarization (PHIP) technique, the NVision team is applying breakthroughs in quantum physics, chemistry, and engineering to revolutionize metabolic MRIs.
“The impact that this technology will have on medicine is monumental,” said Dr. Sella Brosh, CEO of NVision. “With more accessibility to this kind of technology and giving doctors more time to choose the right therapy for treatment, we can significantly improve a patient’s chance of recovery while not subjecting them to toxic treatments that hurt more than they help. Certainty will become the cornerstone of a new, life-altering era of adaptive cancer treatment that gives patients and their loved ones peace of mind.”
With a partnership already in place with Siemens Healthineers, a leading provider of MRI technology, plans to deploy systems at over 50 of the world’s top cancer centers by 2025, and a signed collaboration with Memorial Sloan Kettering, NVision is poised for market disruption.
Congratulations to the team on achieving this milestone. You can find more details about the funding round here.